Tag: vaccine
Vaxxas’ needle-free seasonal influenza vaccine enters clinical trial
Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.
Queensland to open new $280m mRNA vaccine hub with Sanofi
The Queensland government has invested $280 million in a partnership with Sanofi to establish the Translational Science Hub, providing a boost for the next-generation mRNA vaccine research in the state.
South Australian-made pneumococcal vaccine to undergo human trials
GPN Vaccines, a South Australian biotech company, has successfully developed a new universal vaccine that targets a pneumonia-causing bacterium.
Developed in collaboration with the University...
CSIRO opens ‘missing link’ lab to developing Australian vaccine pipeline
Media Release by CSIRO
CSIRO, Australia’s national science agency, has opened a new $23.1 million national lab in Melbourne that will bolster the nation’s ability...
$1.3B Modern Manufacturing Initiative now open for medical product manufacturers
The Morrison Government has opened the funding round for projects in the medical products manufacturing sector under the Modern Manufacturing Initiative (MMI).
Australia's medicine industry...
CSL partners with University of Queensland and CEPI to advance development and manufacture of...
Media Release
CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into a...
GSK Australia opens new $8m pilot vaccine plant in Victoria (VIDEO)
Leading research-based pharmaceutical and healthcare company GSK Australia has opened a new vaccine plant in Boronia, Victoria.
The new pilot plant is the result of...
Vaccine manufacturer CSL announces share buyback and promises to stay as an Australian company
Biopharmaceutical company CSL Limited has announced a further on-market share buyback of up to A$950 million over 12 months.
At the company’s Annual General Meeting...